-
May 9, 2011
For busy doctors, apps are the cure
When Dr. Jose Soler got a late-night call about a critically ill patient, he grabbed his iPad and checked the results of the electrocardiogram test that just had been administered. Thanks to an app that zooms within half a millimeter of every heartbeat rhythm variation, Soler made a diagnosis within two minutes.
Read More
-
May 6, 2011
75 Percent of Physicians Prefer Apple iPad, iPhone: Survey
With the rapid growth of mobile devices in health care, 75 percent of doctors in the United States own some form of Apple device (iPhone, iPad, or iPod), according to a new study by Manhattan Research.
Read More
-
May 4, 2011
Mobile mania: smartphone users dialing up health info; docs prefer Apple
Another day, another batch of survey data showing that smartphones have become the tail wagging the dog in medical media.
Read More
-
May 4, 2011
Non-Hodgkin's lymphoma drug market "will more than double" by 2019
Sales of drugs to treat non-Hodgkin's lymphoma are set to more than double in value over the next decade, increasing in seven major world markets from around $4 billion in 2009 to $8.4 billion by 2019, according to new forecasts.
Read More
-
April 29, 2011
The drug evaluators
As health care costs skyrocket and the federal health overhaul expands the number of patients newly covered by insurance, the federal government and private insurers are increasingly demanding to know which drugs and medical devices work best. Massachusetts is shaping up to be a hotbed of so-called comparative effectiveness research, which seeks to answer those questions.
Read More
-
April 17, 2011
Novo Nordisk strives to find a drug to combat obesity
Novo Nordisk, undaunted by the pharmaceutical industry’s recent failures in the field, is pushing ahead on the development of a new drug to treat obesity as part of its effort to fight diabetes.
Read More
-
April 8, 2011
Bayer/J&J Attempt At New Lands For Xarelto Backfires With MAGELLAN
A trial designed to expand the market for Bayer HealthCare/Johnson & Johnson's oral anticoagulant Xarelto (rivaroxaban) instead has highlighted that the drug has a worse bleeding profile than Sanofi-Aventis' low molecular weight heparin Lovenox (enoxparin) in patients hospitalized with acute illnesses.
Read More
-
March 28, 2011
Report: 2 firms dominate Hampton Roads' insurance market
Two companies dominate commercial health insurance in Hampton Roads, according to a recent report from the American Medical Association.
Read More
-
March 18, 2011
Amarin Version 3.0 Weighs Its Options on Promising Omega-3 Pipeline
Feisty Amarin is certainly undergoing a reincarnation.
Read More
-
March 17, 2011
Key European consumer and physician eHealth trends for 2011
The Internet has drastically changed how both consumers and physicians gather medical information and consume media.
Read More
-
March 17, 2011
What’s in Store for Pharma Marketing in the Year Ahead?
Looking toward the year ahead, a few themes are common across pharma companies and agencies large and small.
Read More
-
March 14, 2011
HIV Drug Development Falters as Merck, Bristol-Myers Struggle With Success
Gilead Sciences Inc., the world’s biggest AIDS-drug maker, revolutionized treatment and helped forge a $15 billion market with a single daily pill attacking the virus with three medicines at once.
Read More
-
March 13, 2011
USA Mobility jumping from pagers to smartphones, tablets with acquisition of Amcom
Springfield-based USA Mobility saw its subscribers dwindle from 6 million in 2004 to 1.9 million at the end of last year as the expansion of text messaging and smartphone use continued to rattle its paging business. In many ways, it was a living relic of a bygone era in telecommunications.
Read More
-
March 11, 2011
Website Development: Build it Right and They Will Come
The number of adult consumers seeking pharma information online has more than doubled since 2005, up from 55 million to 112 million last year according to Manhattan Research's 2010 ePharma Consumer v10.0 study. Not surprisingly, pharma spend in digital channels has also increased.
Read More
-
March 10, 2011
With Pradaxa On The Rise, Medco Gathers Evidence On Warfarin Diagnostic Testing
Pharmacy benefits management company Medco Health Solutions Inc. says that with the newly approved oral anticoagulant Pradaxa (dabigatran) off to a good commercial start, it plans to monitor outcomes and compare results with generic warfarin that has been optimized according to genetic testing.
Read More